Tokyo Tape
Sign in
← Carna Biosciences

Quarterly report · Q1

4572.TEDINET S100QP76
Period2023-01-01 → 2023-03-31
Filed2023-05-11
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥227m2023-01-01 → 2023-03-31Cons.Net sales
Revenue¥1.4bn2022-01-01 → 2022-12-31Cons.Net sales (5-year summary)
Revenue¥555m2022-01-01 → 2022-03-31Cons.Net sales
Operating income−¥506m2023-01-01 → 2023-03-31Cons.Operating income
Operating income¥1m2022-01-01 → 2022-03-31Cons.Operating income
Ordinary income−¥513m2023-01-01 → 2023-03-31Cons.Ordinary income
Ordinary income−¥1.3bn2022-01-01 → 2022-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥5m2022-01-01 → 2022-03-31Cons.Ordinary income
Profit before tax−¥514m2023-01-01 → 2023-03-31Cons.Income before income taxes
Profit before tax−¥11m2022-01-01 → 2022-03-31Cons.Income before income taxes
Net income (owners)−¥519m2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.3bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥15m2022-01-01 → 2022-03-31Cons.Profit loss attributable to owners of parent
Net income−¥519m2023-01-01 → 2023-03-31Cons.Profit loss
Net income−¥15m2022-01-01 → 2022-03-31Cons.Profit loss
Total assets¥4.9bnat 2023-03-31Cons.Assets
Total assets¥4.3bnat 2022-12-31Cons.Assets
Total assets¥5.4bnat 2022-03-31Cons.Total assets (5-year summary)
Total liabilities¥547mat 2023-03-31Cons.Liabilities
Total liabilities¥625mat 2022-12-31Cons.Liabilities
Net assets / equity¥4.4bnat 2023-03-31Cons.Net assets
Net assets / equity¥3.6bnat 2022-12-31Cons.Net assets
Net assets / equity¥4.5bnat 2022-03-31Cons.Net assets (5-year summary)
Cash and deposits¥4.1bnat 2023-03-31Cons.Cash and deposits
Cash and deposits¥3.4bnat 2022-12-31Cons.Cash and deposits
EPS (basic)¥-32.782023-01-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-99.12022-01-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.122022-01-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
Equity ratio88.8%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio85.0%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio84.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 10
SegmentItemPeriodValue
jpcrp040300-q1r_E00987-000Drug Discovery Businessreportable segmentsegment profit2023-01-01 → 2023-03-31−¥570m
jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2023-01-01 → 2023-03-31¥227m
jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2023-01-01 → 2023-03-31¥227m
jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2023-01-01 → 2023-03-31¥64m
jpcrp040300-q1r_E00987-000Drug Discovery Businessreportable segmentrevenue2022-01-01 → 2022-03-31¥286m
jpcrp040300-q1r_E00987-000Drug Discovery Businessreportable segmentrevenue external2022-01-01 → 2022-03-31¥286m
jpcrp040300-q1r_E00987-000Drug Discovery Businessreportable segmentsegment profit2022-01-01 → 2022-03-31−¥108m
jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2022-01-01 → 2022-03-31¥269m
jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2022-01-01 → 2022-03-31¥269m
jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2022-01-01 → 2022-03-31¥109m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 304
ItemContextValueUnit
Guarantee commission noePrior1YTDDuration246000JPY
Guarantee commission noeCurrentYTDDuration239000JPY
Stock issuance cost noePrior1YTDDuration622000JPY
Stock issuance cost noeCurrentYTDDuration4618000JPY
Foreign exchange losses noePrior1YTDDuration－JPY
Foreign exchange losses noeCurrentYTDDuration2015000JPY
Non operating expensesPrior1YTDDuration2502000JPY
Non operating expensesCurrentYTDDuration7769000JPY
Ordinary incomePrior1YTDDuration4576000JPY
Ordinary incomeCurrentYTDDuration-513368000JPY
Impairment loss elPrior1YTDDuration15386000JPY
Impairment loss elCurrentYTDDuration462000JPY
Extraordinary lossPrior1YTDDuration15386000JPY
Extraordinary lossCurrentYTDDuration462000JPY
Income before income taxesPrior1YTDDuration-10809000JPY
Income before income taxesCurrentYTDDuration-513831000JPY
Income taxes currentPrior1YTDDuration4325000JPY
Income taxes currentCurrentYTDDuration5407000JPY
Income taxes deferredPrior1YTDDuration-30000JPY
Income taxes deferredCurrentYTDDuration-28000JPY
Income taxesPrior1YTDDuration4295000JPY
Income taxesCurrentYTDDuration5378000JPY
Profit lossPrior1YTDDuration-15104000JPY
Profit lossCurrentYTDDuration-519210000JPY
Profit loss attributable to owners of parentPrior1YTDDuration-15104000JPY
Profit loss attributable to owners of parentCurrentYTDDuration-519210000JPY
Profit lossPrior1YTDDuration-15104000JPY
Profit lossCurrentYTDDuration-519210000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration-701000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration-101000JPY
Deferred gains or losses on hedges net of tax ociPrior1YTDDuration34990000JPY
Deferred gains or losses on hedges net of tax ociCurrentYTDDuration-615000JPY
Foreign currency translation adjustment net of tax ociPrior1YTDDuration12206000JPY
Foreign currency translation adjustment net of tax ociCurrentYTDDuration1648000JPY
Other comprehensive incomePrior1YTDDuration46494000JPY
Other comprehensive incomeCurrentYTDDuration932000JPY
Comprehensive incomePrior1YTDDuration31390000JPY
Comprehensive incomeCurrentYTDDuration-518278000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration31390000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration-518278000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration－JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration－JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember268605000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember286045000JPY
Revenues from external customersPrior1YTDDuration554650000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember268605000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember286045000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-12-31pass
balance sheet identityconsolidated 2023-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2022-01-01/2022-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass